Surface Oncology is developing SRF617, a fully human antibody designed to promote anti-tumor immunity and inhibit the immunosuppressive activity of the CD39 enzyme. #immunooncology https://t.co/qB2AhVgOl5
Surface Oncology is developing SRF617, a fully human antibody designed to promote anti-tumor immunity and inhibit the immunosuppressive activity of the CD39 enzyme. #immunooncology https://t.co/qB2AhVgOl5